AQST - Aquestive Therapeutics Inc
NYSE * Health Care * Pharmaceuticals
$4.27
+$0.07 (+1.67%)
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQST Key Statistics
Market Cap
$512.41M
EPS
$-0.70
Revenue Growth
+0.1%
Profit Margin
-1.9%
Employees
147
How AQST Compares to Peers
P/E Rank
N/A
of 1
Margin Rank
#2
of 2
Growth Rank
#2
of 2
Size Rank
#2
of 2
Aquestive Therapeutics Inc Company Information
- Headquarters
- New Jersey; U.S.A
- Website
- www.aquestive.com
- Sector
- Health Care
- Industry
- Pharmaceuticals